Vasoactive medications in extremely low gestational age neonates during the first postnatal week

Objective The management of early hypotension in extremely low gestational age neonates (ELGANs) varies greatly between centers. The objective of this study was to provide updated data on the use of vasoactive medications in ELGANs during the first postnatal week. Study design We identified ELGANs (...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of perinatology 2021-09, Vol.41 (9), p.2330-2336
Hauptverfasser: Miller, Laura E., Laughon, Matthew M., Clark, Reese H., Zimmerman, Kanecia O., Hornik, Christoph P., Aleem, Samia, Brian Smith, P., Greenberg, Rachel G.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objective The management of early hypotension in extremely low gestational age neonates (ELGANs) varies greatly between centers. The objective of this study was to provide updated data on the use of vasoactive medications in ELGANs during the first postnatal week. Study design We identified ELGANs (22–27 weeks gestational age) cared for at Pediatrix neonatal intensive care units from 2009 to 2018. We evaluated the frequency of exposure to vasoactive medications by gestational age, and compared use of vasoactive medications between two epochs (2009–2013 and 2014–2018). Results A total of 10,070/34,234 (29%) ELGANs received ≥1 vasoactive medication. Dopamine was the most frequently used vasoactive medication. The majority (83%) of treated ELGANs initiated therapy on postnatal days 0–1. Overall use of vasoactive medications was slightly lower in 2014–2018 than 2009–2013 (28 vs 31%, p  
ISSN:0743-8346
1476-5543
DOI:10.1038/s41372-021-01031-8